Paper - WANFANG MED ONLINE

You Position: Home > Paper

Research progress of virtual screening aided drug discovery

( views:53, downloads:0 )

Author:: No author available

Journal Title:: ACTA PHARMACEUTICA SINICA

Issue:: 6

DOI:: 10.3321/j.issn:0513-4870.2009.06.002

Key Word:: 虚拟筛选;非类药化合物;药效团;分子对接;分子相似性

Abstract：在新药发现过程中,虚拟筛选的应用可以富集活性化合物,降低筛选成本,提高药物筛选的可行性,因此已成为新药发现的重要方法.虚拟筛选与生物活性筛选的结合,可以优势互补,有效地促进新药的发现.本文介绍了非类药化合物排除、假阳性化合物排除、药效团搜索、分子对接计算以及分子相似性分析等几种方法在药物发现中的应用及其发展趋势,以期更好地应用虚拟筛选方法,促进新药的快速发现.

Reference

[1]刘艾林,杜冠华.乙酰胆碱酯酶抑制剂虚拟筛选方法研究[J].2003,(5).
[2]LIU Ailin,CAO Hongpeng,DU Guanhua.Drug screening for influenza neuraminidase inhibitors[J].2005,(1).
[3]Hachet-Haas M,Springael JY,Kellenberger E,etc.Identification of nonpeptide CCR5 receptor agonists by structure-based virtual screening.[J].2007,50(6).
[4]Pooja Sharma,Nanda Ghoshal.Exploration of a Binding Mode of Benzothiazol-2-yl Acetonitrile Pyrimidine Core Based Derivatives as Potent c-Jun N-Terminal Kinase-3 Inhibitors and 3D-QSAR Analyses[J].2006,46(4).
[5]Wolber G,Laggner C,Steindl TM,etc.High-throughput structure-based pharmacophore modelling as a basis for successful parallel virtual screening[J].2006,20(12).
[6]Krasowski MD,Ekins S,Kortagere S.The importance of discerning shape in molecular pharmacology.[J].2009,30(3).
[7]Engel S,Skoumbourdis AP,Childress J,etc.A virtual screen for diverse ligands: Discovery of selective G protein-coupled receptor antagonists[J].2008,130(15).
[8]B K, Shoichet,R M, Stroud,D V, Santi,etc.Structure-based discovery of inhibitors of thymidylate synthase.[J].1993,259.
[9]Lengauer T,Lemmen C,Rarey M,etc.Novel technologies for virtual screening.[J].2004,9(1).
[10]Feher M.Consensus scoring for protein-ligand interactions.[J].2006,11(9).
[11]McInnes C.Improved lead-finding for kinase targets using high-throughput docking.[J].2006,9(3).
[12]Guido RV,Oliva G,Andricopulo AD.Virtual screening and its integration with modern drug design technologies.[J].2008,15(1).
[13]Nikil, Wale,George, Karypis,Ian A, Watson.Method for effective virtual screening and scaffold-hopping in chemical compounds.[J].2007,6.
[14]Cheeseright TJ,Vinter JG,Melville JL,etc.FieldScreen: Virtual Screening Using Molecular Fields. Application to the DUD Data Set[J].2008,48(11).
[15]Asano S,Sato H,Kusunose N,etc.Identification of phosphodiesterase-1 and 5 dual inhibitors by a ligand-based virtual screening optimized for lead evolution.[J].2006,16(5).
[16]Adrian H.Elcock,William M.Rockey.Structure Selection for Protein Kinase Docking and Virtual Screening:Homology Models or Crystal Structures?[J].2006,7(5).
[17]Sun H.Pharmacophore-based virtual screening.[J].2008,15(10).
[18]Golub AG,Yakovenko OY,Bdzhola VG,etc.Evaluation of 3-carboxy-4(1H)-quinolones as inhibitors of human protein kinase CK2[J].2006,49(22).
[19]Gilbert M. Rishton.Reactive compounds and in vitro false positives in HTS[J].1997,2(9).
[20]Neres J,Brewer ML,Ratier L,etc.Discovery of novel inhibitors of Trypanosoma cruzitrans-sialidase from in silico screening.[J].2009,19(3).
[21]Corbeil CR,Englebienne P,Yannopoulos CG,etc.Docking Ligands into flexible and solvated macromolecules. 2. Development and application of FITTED 1.5 to the virtual screening of potential HCV polymerase inhibitors[J].2008,48(4).
[22]Shrestha AR,Ali HI,Ashida N,etc.Antitumor studies. Part 5: Synthesis, antitumor activity, and molecular docking study of 5-(monosubstituted amino)-2-deoxo-2-phenyl-5-deazaflavins.[J].2008,16(20).
[23]Waszkowycz B.Towards improving compound selection in structure-based virtual screening.[J].2008,13(5).
[24]Zhu W,Chen K,Tan X,etc.Discovering potassium channel blockers from synthetic compound database by using structure-based virtual screening in conjunction with electrophysiological assay.[J].2007,50(1).
[25]Price S,Bordogna W,Bull RJ,etc.Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.[J].2007,17(2).
[26]Piedrafita FJ,Cavasotto CN,Abagyan RA,etc.In silico identification of novel EGFR inhibitors with antiproliferative activity against cancer cells.[J].2006,16(7).
[27]Lushington GH,Guo JX,Wang JL.Whither combine? New opportunities for receptor-based QSAR.[J].2007,14(17).
[28]George D, Geromichalos.Importance of molecular computer modeling in anticancer drug development.[J].2007,12 Suppl 1.
[29]Rizzi A,Fioni A.Virtual screening using PLS discriminant analysis and ROC curve approach: An application study on PDE4 inhibitors[J].2008,48(8).
[30]von Korff M,Freyss J,Sander T.Flexophore, a new versatile 3D pharmacophore descriptor that considers molecular flexibility[J].2008,48(4).
[31]Ajay N.Jain.Scoring Functions for Protein-Ligand Docking[J].2006,7(5).
[32]Jorgensen WL,Tirado-Rives J.Contribution of conformer focusing to the uncertainty in predicting free energies for protein-ligand binding[J].2006,49(20).
[33]Castro EA,Talevi A,Prieto JJ,etc.New similarity-based algorithm and its application to classification of anticonvulsant compounds.[J].2007,22(3).
[34]T, Langer,R D, Hoffmann.Virtual screening: an effective tool for lead structure discovery?[J].2001,7(7).